They found that treatment induced the expression of several immune checkpoints (B7-H3, CTLA4, PDL1, and PDL2) within prostate tumors, suggesting the potential for combining BT and immune checkpoint blockade [116]. The gene discussed is CD274; the disease is prostate neoplasm.